Stem Cell Cord Blood ‘Banking’ Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
According to Koos, “Companies like Bio-Matrix are making use of a ready-made patient customer base by linking up with hospitals, medical institutes, research institutions and biotechnology companies to assist in stem cell research and treatments. For hospitals, this kind of marketing partnership is synergistic at its roots because hospitals would promote cord blood storage banks leading to additional revenue from every newborn baby delivered. Many hospitals are starting this kind of cord blood business as part of their gynecological services because it’s a natural extension of the basic service hospitals provide already and is a cash-rich add on as well.”
Koos said that BMSN intends to expand its own marketing program to include stem cell therapy centers. “We are looking for strategic alliances with hospitals and research centers on a global level. The Company believes it can assist these medical institutions in better educating parents about cord blood banking. We are also in the midst of identifying regional and local partners whom we can work with.”
About Bio-Matrix Scientific Group
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
SOURCE Bio-Matrix Scientific Group Inc.